Evidence map›Paper›PMID 28345027›Full record

ArticleMolecular therapy oncolytics2017

Pre-clinical Assessment of C134, a Chimeric Oncolytic Herpes Simplex Virus, in Mice and Non-human Primates.

Kevin A Cassady, David F Bauer, Justin Roth, Melissa R Chambers, Trent Shoeb, Jennifer Coleman, Mark Prichard, G Yancey Gillespie, James M Markert

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy oncolytics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
3.1field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 50 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Oncolytic HSV and cancer drug interactions: Current clinical status and future directions.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Safety and Efficacy of Intraventricular Immunovirotherapy with Oncolytic HSV-1 for CNS Cancers.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022
    Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Kevin A CassadyDepartment of Pediatrics, Research Institute Center for Childhood Cancer and Blood Disorders, Nationwide Children's Hospital, Columbus, OH 43212, USA; Ohio State University College of Medicine, Columbus, OH 43210, USA.
David F BauerDepartment of Neurosurgery, University of Alabama, Birmingham, AL 35294, USA.
Justin RothDepartment of Pediatrics, University of Alabama, Birmingham, AL 35294, USA.
Melissa R ChambersDepartment of Neurosurgery, University of Alabama, Birmingham, AL 35294, USA.
Trent ShoebDepartment of Neurosurgery, University of Alabama, Birmingham, AL 35294, USA.
Jennifer ColemanDepartment of Neurosurgery, University of Alabama, Birmingham, AL 35294, USA.
Mark PrichardDepartment of Pediatrics, University of Alabama, Birmingham, AL 35294, USA.
G Yancey GillespieDepartment of Neurosurgery, University of Alabama, Birmingham, AL 35294, USA; Department of Pediatrics, University of Alabama, Birmingham, AL 35294, USA; Department of Comparative Medicine, University of Alabama, Birmingham, AL 35294, USA.
James M MarkertDepartment of Neurosurgery, University of Alabama, Birmingham, AL 35294, USA; Department of Pediatrics, University of Alabama, Birmingham, AL 35294, USA; Department of Comparative Medicine, University of Alabama, Birmingham, AL 35294, USA.
University of Alabama at Birmingham · USNationwide Children's Hospital · US

Funding

CONTEMPORARY THERAPEUTICS FOR ANAPLASTIC GLIOMASP20CA151129 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI GILLESPIE, G. YANCEY · 2011 to 2013
$2.3M
NCI NIH HHS P20 CA151129
6 · The paper itself

Abstract

Oncolytic herpes simplex virus (oHSV) type I constructs are investigational anti-neoplastic agents for a variety of malignancies, including malignant glioma. Clinical trials to date have supported the safety of these agents even when directly administered in the CNS. Traditional pre-clinical US Food and Drug Administration (FDA) toxicity studies for these agents have included the use of two species, generally including murine and primate studies. Recently, the FDA has decreased its requirement of non-human primates as an animal model for ethical reasons, especially for established viral systems where there are good alternative model systems. Here we present data demonstrating the safety of C134, a chimeric oHSV construct, in CBA mice as well as in a limited number of the HSV-sensitive non-human primate

Indexed as

alpha US11gliomaHSVinterferonIRF3IRS1neurotoxicologyoncolytic virusPKRγ134.5Δ

Identifiers

PMID28345027
PMCPMC5363760
OpenAlexW2594415105

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.